블로그
-
Tirzepatide sodium salt [B1370-449939][CAS no. 2933217-72-0]_BOC Sciences - 코아사이언스
It works by stimulating insulin secretion in response to meals and suppressing glucagon secretion, thereby It also slows gastric emptying, which contributes to its glucose-lowering effects.
blog.naver.com · 2026.08.04
-
[U.S. FDA] FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Adv
Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor
blog.naver.com · 2026.08.07
-
[PROTACs/LYTACs] Tri-GalNAc-NHS ester [DC72546][CAS no. 1953146-83-2]_DC Chemicals - 코아사이언스
ASGPR is a lysosomal targeting receptor specifically expressed on liver cells, for the degradation of 추천 상품 [Say "Goodbye" to gradient gel !!] AllView PAGE Buffer [DS520.......
blog.naver.com · 2026.07.03
-
VK-II-86 [122964][CAS no. 955371-84-3]_MedKoo Biosciences - 코아사이언스
It targets the ryanodine receptor 2 (RyR2) channel, inhibiting store-overload-induced calcium release Therapeutically, VK-II-86 has been shown to prevent hypokalaemia-induced ventricular arrhythmias by normalizing
blog.naver.com · 2026.07.22
-
Tirzepatide Acetate [TP1111L][Cas No. 2023788-19-2 (free base)]_TargetMol - 코아사이언스
From discovery to clinical proof of concept. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
blog.naver.com · 2026.06.26
-
GalNAc-L96-CPG [BOC-023][CAS no. -]_BOC Sciences - 코아사이언스
It consists of a triantennary GalNAc ligand (specifically the L96 variant) covalently attached to a controlled The GalNAc moiety serves as a high-affinity ligand for the asialoglycoprotein receptor (ASGPR), which
blog.naver.com · 2026.06.12
-
Human LGR5 ELISA Kit [EH9777]_FineTest - 코아사이언스
Human LGR5(Leucine-rich repeat-containing G-protein coupled receptor 5) ELISA Kit Cat.# EH9777 / Size Then, it binds with LGR5 bound to precoated antibody.
blog.naver.com · 2026.06.16
-
크릴 오일이 단식이나 위고비, 마운자로와 같은 GLP-1 주사로 인한 체중 감량시의 부작용인 근육 손실(오젬픽 페이스)을 억제할 수 있다는 연구
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight
blog.naver.com · 2025.10.21
-
크릴 오일이 단식이나 위고비, 마운자로와 같은 GLP-1 주사로 인한 체중 감량시의 부작용인 근육 손실(오젬픽 페이스)을 억제할 수 있다는 연구
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight
blog.naver.com · 2025.10.21
-
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ ...
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast However, resistance to this treatment and disease progression remains a major clinical challenge.
blog.naver.com · 2025.07.10
블로그 결과 더보기 →
